Last $0.99 USD
Change Today +0.0021 / 0.21%
Volume 169.1K
VICL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

vical inc (VICL) Snapshot

Open
$1.00
Previous Close
$0.99
Day High
$1.00
Day Low
$0.97
52 Week High
03/3/14 - $1.60
52 Week Low
12/16/14 - $0.89
Market Cap
89.7M
Average Volume 10 Days
355.5K
EPS TTM
$-0.19
Shares Outstanding
90.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VICAL INC (VICL)

vical inc (VICL) Related Bloomberg News

View More Bloomberg News

vical inc (VICL) Related Businessweek News

No Related Businessweek News Found

vical inc (VICL) Details

Vical Incorporated is engaged in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its product candidates include CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic and prophylactic vaccines for herpes simplex virus type 2, which are under Phase 1/2 clinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission. The company, through corporate collaborations, is also developing TransVax, which is in Phase III clinical trial to protect against CMV infection after stem cell transplants, as well as in Phase II clinical trial for prevention of CMV infection in kidney transplant recipients; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to enhance survival time of dogs with oral melanoma. In addition, Vical Incorporated, through government collaboration, is developing Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all four dengue serotypes. Further, it is also engaged in contract manufacturing of plasmid investigational products for various clients. The company was founded in 1987 and is headquartered in San Diego, California.

vical inc (VICL) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $557.0K
Chief Accounting Officer and Vice President o...
Total Annual Compensation: $229.2K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $271.8K
Vice President of Vaccine Research
Total Annual Compensation: $267.8K
Compensation as of Fiscal Year 2013.

vical inc (VICL) Key Developments

Vical Incorporated Reports Financial Results for the Three Months and Twelve Months Ended December 31, 2014

Vical Incorporated reported financial results for the three months and twelve months ended December 31, 2014. Net loss for the fourth quarter of 2014 was $4.6 million, or $0.05 per share, compared with a net loss of $2.2 million, or $0.03 per share, for the fourth quarter of 2013. The increase in the company's net loss compared to the fourth quarter of 2013 was due primarily to increased expenses related to its HSV-2 program. Revenues were $4.8 million, compared with revenues of $3.1 million for the fourth quarter of 2013, reflecting higher revenues from Astellas Pharma Inc. for development and manufacturing services performed under the company's ASP0113 collaborative agreements. Loss from operations was $4.7 million compared to $2.22 million a year ago. Net loss was $16.5 million, or $0.19 per basic and diluted share, compared with a net loss of $31.24 million, or $0.36 per basic and diluted share a year ago. Revenues were $15.217 million, compared with revenues of $7.72 million a year ago. Loss from operations was $16.63 million compared to $31.4 million a year ago.

Vical Incorporated Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

Vical Incorporated Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

Vical Incorporated to Report Q4, 2014 Results on Feb 26, 2015

Vical Incorporated announced that they will report Q4, 2014 results at 12:00 PM, US Eastern Standard Time on Feb 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VICL:US $0.99 USD +0.0021

VICL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VICL.
View Industry Companies
 

Industry Analysis

VICL

Industry Average

Valuation VICL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VICAL INC, please visit www.vical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.